Suzanne M. Hanlon is CLO & VP +1 at Zynerba Pharmaceuticals, Inc. (ZYNE). They have made 4 open-market trades across 1 company since 2015, most recently 2021-01-21.
CIK 0001621443
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
3 open-market purchases totalling $130K since 2015, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| ZYNE | 80,693 | $105K |
Shares reported on the most recent Form 4, priced at the 2021-01-25 close.
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.